Ongoing collaboration with the integration of two advanced predictive models into the InSilicoTrials platform
COSBI and InSilicoTrials have strengthened their ongoing collaboration with the integration of two advanced predictive models into the InSilicoTrials platform.
These new models – focused on prostate cancer – are designed to support researchers and pharmaceutical companies in accelerating the development of safer, more effective therapies. They provide key insights into immunotherapy strategies and optimized administration protocols for castration-resistant prostate cancer (CRPC).
This initiative reflects our continued commitment to making cutting-edge simulation technologies more accessible and impactful in drug development.
Read the full press release to learn more.
#InSilicoTrials #COSBI #DrugDevelopment #ProstateCancer #DigitalHealth #SystemsPharmacology #InSilicoMedicine #PrecisionMedicine #HealthcareInnovation
